Full Archive
The protein UHRF1 could help people survive pleural mesothelioma. Research from the National Cancer Institute found this protein. The protein is encoded by the gene with the same name. Researchers in the study believe that it could cause the growth and spread of mesothelioma. The information needs to be confirmed with a larger study but…
A new clinical trial at the Memorial Sloan Kettering Cancer Center is recruiting patients for a pleural mesothelioma study. The treatment involves T-cell therapy and is a very promising treatment for mesothelioma sufferers. The reason the study is being done is ATA2271, which is known as CAR T-cell therapy, was recently approved by the Food…
This study will test the safety of MSLN-targeted CAR-T cells at different doses to find the safest dose to give to people with MPM. The researchers want to see what effects, if any, the study treatment has on people with this type of cancer. This study is the first time that an MSLN-targeted CAR-T cell treatment with an anti-PD1 component is being given to people.
A new treatment has been approved for mesothelioma by the Food and Drug Administration (FDA). The treatment uses a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), which are immunotherapy drugs created by Bristol-Myers Squibb. It is the first new drug combination approved for mesothelioma in 16 years. The most recent approved treatment involved Tumor Treating…
Mesothelioma is a cancer with a bad prognosis that is primarily caused by asbestos exposure. There is no cure for mesothelioma, so people diagnosed with the disease do not have a great chance of living long past their diagnoses. Clinical trials are people’s best chance of finding a better treatment or even a cure, so…
A new mesothelioma clinical trial is taking place in Oslo, Norway. The trial is looking at the UV1 cancer vaccine alongside immunotherapy. The vaccine is a peptide-based drug that activates a T-cell response, allowing the immunotherapy drugs to work better. This will be the first time that UV1 is being tested on mesothelioma, but it…
Primary Outcome Measures The probability of rejecting the investigational treatment is at least 81%, if the DLT rate is greater than 33% and the probability of accepting the treatment is at least 71% if the DLT rate is less than a safe level of 17%. [ Time Frame: up to 27 days ] Safety will be assessed by the…
A clinical trial being tested on lung cancer could potentially be a good treatment for people with mesothelioma. The combination of Keytruda and Tumor Treating Fields is being tested for non-small cell lung cancer. Keytruda is an immune checkpoint inhibitor that allows the immune system to find cancer cells hiding within the PD-1 pathway. It…
In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient’s tumor shrink or stop growing.
The combination of Yervoy and Opdivo was tested on mesothelioma and the overall survival was promising. The overall survival was 18.1 months versus 14.1 months for patients receiving just chemotherapy. This is the first time that a phase III trial had an improved survival with an immunotherapy combination in a first line setting. Doctors doing…
